검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tislelizumab |
Overview Company | BeiGene |
Overview Modality | ANTIBODY |
Overview Target | Advanced Solid Tumor |
Overview Indication | Locally Recurrent Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target genes of these miRNAs were involved in key signaling pathways including MAPK and Ras signaling |
MoA Biomarker | PD-L1 expression |
PK/PD Half-life | 24 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report.. Tislelizumab, an immune checkpoint inhibitor, is widely used in the treatment of various malignancies; however, its immune-related adverse events(irAEs) require careful attention. Here, we report a case of a patient with recurrent urothelial carcinoma who developed myositis and … |
Clinical Primary efficacy | ORR 37.1% |
Clinical ORR | 37.1% |
Clinical Result source | ClinicalTrials.gov NCT04948697 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tislelizumab |
Overview Company | BeiGene |
Overview Modality | ANTIBODY |
Overview Target | Advanced Solid Tumor |
Overview Indication | Locally Recurrent Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target genes of these miRNAs were involved in key signaling pathways including MAPK and Ras signaling |
MoA Biomarker | PD-L1 expression |
PK/PD Half-life | 24 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report.. Tislelizumab, an immune checkpoint inhibitor, is widely used in the treatment of various malignancies; however, its immune-related adverse events(irAEs) require careful attention. Here, we report a case of a patient with recurrent urothelial carcinoma who developed myositis and … |
Clinical Primary efficacy | ORR 37.1% |
Clinical ORR | 37.1% |
Clinical Result source | ClinicalTrials.gov NCT04948697 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교